Comparison of Leqembi to Precision Medicine
On July 5th 2023, the FDA gave full approval for Leqembi, which is a monoclonal antibody for patients with amyloid and mild cognitive impairment.
Here is a brief summary on how the drug stacks against the Precision Medicine Approach we are using; We are happy to discuss this issue further with anyone in our community.
References
Van Dyck et al. Lecanemab in early Alzheimer’s Disease N Engl J Med 2023; 388:9-21 DOI: 10.1056/NEJMoa2212948
https://www.nytimes.com/2023/07/06/health/leqembi-alzheimers-drug.html?searchResultPosition=1
Toups et al. Precision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project. Journal of Alzheimer’s Disease 88 (2022) 1411-1421.